A multi-institutional, phase IV project to study the feasibility of safely managing patients receiving induction with liposomal daunorubicin and cytarabine (CPX-351) for acute myeloid leukemia (AML) in an outpatient environment

Protocol No
IIT-MICHAELIS-OUTPT-CPX-351
Principal Investigator
Laura Michaelis
Phase
IV
Summary
The purpose of this project is to study the feasibility of giving CPX-351 to adult patients with AML as an outpatient therapy. This study will also monitor the experiences of both the patient and their caregiver on the management of side effects and quality of life.
Description
Outpatient Patients Receiving Induction With Liposomal Daunorubicin & Cytarabine (CPX-351) for AML
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL
Share This: